Ultra Pharmaceuticals has sold the rights to injectables Restylane , Perlane , Emervel , Sculptra and Dysport to Galderma for $ 1.4bn . The sale was previously agreed with Nestlé , which recently acquired Galderma . Ultra Classic and Ultra Ultra are currently awaiting approval from the US Food and Drug Administration and Health Canada .
Valeant Pharmaceuticals has sold the rights to injectables Restylane, Perlane, Emervel, Sculptra and Dysport to Galderma for $1.4bn. The sale was previously agreed with Nestlé, which recently acquired Galderma. Emervel Classic and Emervel Deep are currently awaiting approval from the US Food and Drug Administration and Health Canada.